SMITHFIELD – Novo Nordisk was named Johnston Community College’s 2023 Business and Industry Partner of the Year.
JCC announces this award each year at its annual Breakfast Before Business, a signature networking event for professionals across our region.
Novo Nordisk is one of JCC’s major partners for initiatives such as the Workforce Development Center in Clayton, a collaborative biotechnology training facility, and JOCO WORKS, an event that brings thousands of eighth graders to JCC’s campus for real-world career exploration.
“Our partnership with Novo Nordisk is unique and invaluable to Johnston County’s workforce,” says JCC Vice President of Continuing Education Vic McCormick.
“Novo Nordisk understands that we are all better together,” McCormick adds.
“Without Novo Nordisk and other community partners, our ability to sustain an employment pipeline for Johnston County would be severely diminished,” says JCC President Dr. Vern Lindquist.
“We are grateful to be in a region where collaboration overrides competition,” Lindquist says.
“Novo Nordisk is so proud of our commitment to support Johnston Community College in creating these innovative workforce development programs,” said Gitte Husballe, director of People & Organization at Novo Nordisk’s Active Pharmaceutical Ingredient (API) manufacturing facility in Clayton.
“This partnership has been instrumental to our success in growing our business here in this community, as it has opened up so many opportunities for students to enter meaningful careers in life sciences. This award is a special recognition of all our employees who creatively collaborate with JCC educators to make these initiatives possible,” Husballe adds.
Novo Nordisk is the presenting sponsor for JOCO WORKS, a program operated by the Triangle East Chamber. This year’s event will be held November 7 – 8, 2024 at JCC and is open to eighth graders across the county.
Awesome. Just what we need us more fake drugs to cure fake diseases. People there are natural ways to cure things. Open your mind and do some research. These big pharma fools will pay a price some day.